{"id":"W2954686273","doi":"10.1158/1538-7445.am2019-ct158","title":"Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Ovarian cancer; Nivolumab; Oncology; Internal medicine; Chemotherapy; Debulking; PARP inhibitor; BRCA mutation; Cancer; Cancer research; Immunotherapy; Poly ADP ribose polymerase; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001133738,0.001750627,0.002207141,0.0006842271,0.0004607515,0.001034419,0.001113999,0.001942575,0.01059252],"category_scores_gemma":[0.0007803697,0.0006929725,0.001249348,0.000434257,0.001077353,0.000786551,0.0003537123,0.003109935,0.001899279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006821566,"about_ca_system_score_gemma":0.001378519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00131681,"about_ca_topic_score_gemma":0.003920873,"domain_scores_codex":[0.9996238,0.0001773408,0.0000178907,0.00008123426,0.00002827576,0.00007154064],"domain_scores_gemma":[0.9995729,0.00006099128,0.00007407268,0.0000308813,0.00002682326,0.0002342416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9381464,0.0211392,0.0004620978,0.0008877689,0.0008772378,0.00005825982,0.00004151576,0.000399456,0.009437125,0.0002263432,0.002242645,0.02608188],"study_design_scores_gemma":[0.9224487,0.07440884,0.00110923,0.00003142666,0.0002170494,0.00002651448,0.00001121205,0.0003146718,0.0004735538,0.00009780702,0.0008482007,0.0000128221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9704785,0.006233795,0.001209169,0.0009654671,0.0008354349,0.01088001,0.002781928,0.0005310421,0.006084681],"genre_scores_gemma":[0.964588,0.003108937,0.003179434,0.002892667,0.0004977279,0.01065845,0.002698452,0.00006922038,0.0123072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01059252,"threshold_uncertainty_score":0.0354355,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08737768898067304,"score_gpt":0.4411966240315549,"score_spread":0.3538189350508818,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}